Surface modification of poly(D, L -lactic-co-glycolic acid) nanoparticles with protamine enhanced cross-presentation of encapsulated ovalbumin by bone marrow-derived dendritic cells

Journal of Biomedical Materials Research - Part A

Volumn 96 A, Issue 1, 2011, Pages 142-149

  Han, Ruiling ^a   Zhu, Junming ^a   Yang, Xiangliang ^a   Xu, Huibi ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

antigen delivery system; cross presentation; dendritic cells; PLGA nanoparticles; protamine

Indexed keywords

ANTIGEN DELIVERY SYSTEM; CROSS-PRESENTATION; DENDRITIC CELLS; PLGA NANOPARTICLES; PROTAMINE;

ANTIGENS; BONE; CATALYST ACTIVITY; CELLS; FLOW CYTOMETRY; MOLECULAR BIOLOGY; TRANSMISSION ELECTRON MICROSCOPY;

NANOPARTICLES;

B7 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; INTERLEUKIN 12P70; INTERLEUKIN 4; NANOCOATING; NANOPARTICLE; OVALBUMIN; POLYGLACTIN; PROTAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; ENCAPSULATION; ENDOCYTOSIS; FLOW CYTOMETRY; HYBRIDOMA; LYSOSOME; LYSOSOME MEMBRANE; MALE; MATERIAL COATING; MOUSE; NONHUMAN; PROTEIN MODIFICATION; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION;

ANIMALS; ANTIGENS; BIOCOMPATIBLE MATERIALS; BONE MARROW CELLS; CROSS-PRIMING; DENDRITIC CELLS; DRUG COMPOUNDING; LACTIC ACID; MALE; MATERIALS TESTING; MICE; MICE, INBRED C57BL; NANOPARTICLES; OVALBUMIN; PARTICLE SIZE; POLYGLYCOLIC ACID; PROTAMINES; SURFACE PROPERTIES;

EID: 78649621864     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.32860     Document Type: Article

References (39)

1. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H,. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994; 264: 961-965. (Pubitemid 24196166)
2. Sigal LJ, Crotty S, Andino R, Rock KL,. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 1999; 398: 77-80.
3. Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL,. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci USA 1993; 90: 4942-4946.
4. Gerelchuluun T, Lee YH, Lee YR, Im SA, Song S, Park JS, Han K, Kim K, Lee CK,. Dendritic cells process antigens encapsulated in a biodegradable polymer, poly(D,L -lactide-co-glycolide), via an alternate class I MHC processing pathway. Arch Pharm Res 2007; 30: 1440-1446.
5. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V,. Rapid endo-lysosomal escape of poly(DL -lactide-co-glycolide) nanoparticles: Implications for drug and gene delivery. FASEB J 2002; 16: 1217-1226.
6. Shen H, Ackerman AL, Cody V, Giodini A, Hinson ER, Cresswell P, Edelson RL, Saltzman WM, Hanlon DJ,. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 2006; 117: 78-88.
7. Jiang W, Gupta RK, Deshpande MC, Schwendeman SP,. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev 2005; 57: 391-410.
8. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM,. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L -lactide-co-glycolide) and its derivatives. J Control Release 2008; 125: 193-209.
9. Diwan M, Elamanchili P, Lane H, Gainer A, Samuel J,. Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses. J Drug Target 2003; 11: 495-507.
10. Yoshida M, Mata J, Babensee JE,. Effect of poly(lactic-co-glycolic acid) contact on maturation of murine bone marrow-derived dendritic cells. J Biomed Mater Res A 2007; 80: 7-12.
11. Elamanchili P, Lutsiak CM, Hamdy S, Diwan M, Samuel J,. "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells. J Immunother 2007; 30: 378-395.
12. O'Hagan DT,. Recent advances in immunological adjuvants: The development of particulate antigen delivery systems. Expert Opin Investig Drugs 1998; 7: 349-359.
13. Partidos CD, Vohra P, Jones D, Farrar G, Steward MW, CTL responses induced by a single immunization with peptide encapsulated in biodegradable microparticles. J Immunol Methods 1997; 206: 143-151.
14. Nixon DF, Hioe C, Chen PD, Bian Z, Kuebler P, Li ML, Qiu H, Li XM, Singh M, Richardson J, McGee P, Zamb T, Koff W, Wang CY, O'Hagan D,. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine 1996; 14: 1523-1530.
15. Audran R, Peter K, Dannull J, Men Y, Scandella E, Groettrup M, Gander B, Corradin G,. Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine 2003; 21: 1250-1255.
16. Lofthouse S,. Immunological aspects of controlled antigen delivery. Adv Drug Deliv Rev 2002; 54: 863-870.
17. Storni T, Kündig TM, Senti G, Johansen P,. Immunity in response to particulate antigen-delivery systems. Adv Drug Deliv Rev 2005; 57: 333-355.
18. Yang YW, Hsu PY,. The effect of poly(D,L -lactide-co-glycolide) microparticles with polyelectrolyte self-assembled multilayer surfaces on the cross-presentation of exogenous antigens. Biomaterials 2008; 29: 2516-2526.
19. Martínez Gómez JM, Csaba N, Fischer S, Sichelstiel A, Kündig TM, Gander B, Johansen P,. Surface coating of PLGA microparticles with protamine enhances their immunological performance through facilitated phagocytosis. J Control Release 2008; 130: 161-167.
20. Thomas C, Gupta V, Ahsan F,. Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses. Int J Pharm 2009; 379: 41-50.
21. Sorgi FL, Bhattacharya S, Huang L,. Protamine sulfate enhances lipid-mediated gene transfer. Gene Ther 1997; 4: 961-968. (Pubitemid 27437722)
22. Fischer S, Uetz-von Allmen E, Waeckerle-Men Y, Groettrup M, Merkle HP, Gander B,. The preservation of phenotype and functionality of dendritic cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles. Biomaterials 2007; 28: 994-1004.
23. Martínez Gómez JM, Fischer S, Csaba N, Kündig TM, Merkle HP, Gander B, Johansen P,. A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles. Pharm Res 2007; 24: 1927-1935.
24. Panyam J, Sahoo SK, Prabha S, Bargar T, Labhasetwar V,. Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D,L -lactide-co-glycolide) nanoparticles. Int J Pharm 2003; 262: 1-11.
25. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM,. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992; 176: 1693-1702.
26. Mesa C, de Léon J, Fernández LE,. Very small size proteoliposomes derived from Neisseria meningitidis: An effective adjuvant for generation of CTL responses to peptide and protein antigens. Vaccine 2006; 24: 2692-2699.
27. Karttunen J, Sanderson S, Shastri N,. Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. Proc Natl Acad Sci USA 1992; 89: 6020-6024.
28. Jilek S, Zurkaulen H, Pavlovic J, Merkle HP, Walter E,. Transfection of a mouse dendritic cell line by plasmid DNA-loaded PLGA microparticles in vitro. Eur J Pharm Biopharm 2004; 58: 491-499.
29. Jilek S, Merkle HP, Walter E,. DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells. Adv Drug Deliv Rev. 2005; 57: 377-390.
30. Waeckerle-Men Y, Allmen EU, Gander B, Scandella E, Schlosser E, Schmidtke G, Merkle HP, Groettrup M,. Encapsulation of proteins and peptides into biodegradable poly(D,L -lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells. Vaccine 2006; 24: 1847-1857.
31. Elamanchili P, Diwan M, Cao M, Samuel J,. Characterization of poly(D,L -lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 2004; 22: 2406-2412.
32. Wischke C, Borchert HH, Zimmermann J, Siebenbrodt I, Lorenzen DR,. Stable cationic microparticles for enhanced model antigen delivery to dendritic cells. J Control Release 2006; 114: 359-368.
33. Wischke C, Zimmermann J, Wessinger B, Schendler A, Borchert HH, Peters JH, Nesselhut T, Lorenzen DR,. Poly(I:C) coated PLGA microparticles induce dendritic cell maturation. Int J Pharm 2009; 365: 61-68.
34. Tran KK, Shen H,. The role of phagosomal pH on the size-dependent efficiency of cross-presentation by dendritic cells. Biomaterials 2009; 30: 1356-1362.
35. Czerniecki BJ, Cohen PA, Faries M, Xu S, Roros JG, Bedrosian I,. Diverse functional activity of CD83+ monocyte-derived dendritic cells and the implications for cancer vaccines. Crit Rev Immunol 2001; 21: 157-178.
36. Macatonia SE, Hosken NA, Litton M, Vieira P, Hsieh CS, Culpepper JA, Wysocka M, Trinchieri G, Murphy KM, O'Garra A,. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 1995; 154: 5071-5079.
37. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G,. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996; 184: 747-752.
38. Mehrotra PT, Wu D, Crim JA, Mostowski HS, Siegel JP,. Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes. J Immunol 1993; 151: 2444-2452.
39. Rukavishnikova EV, Korolenko TA, Sassa T, Oka T, Horiuchi S, Natori Y,. Interaction of rat liver lysosomes with basic polypeptides. FEBS Lett 1995; 369: 217-220.